shattuck
labs
present
poster
gamma
delta
cell
engager
platform
society
immunotherapy
cancer
sitc
anniversary
annual
meeting
austin
tx
durham
nc
globe
newswire
shattuck
labs
shattuck
nasdaq
sttk
biotechnology
company
pioneering
development
fusion
proteins
new
class
biologic
medicine
treatment
patients
cancer
autoimmune
disease
today
announced
preclinical
data
gamma
delta
cell
engager
platform
accepted
poster
presentation
society
immunotherapy
cancer
sitc
anniversary
annual
meeting
held
virtually
november
presentation
details
title
vivo
expansion
gamma
delta
cells
butyrophilin
heterodimer
leads
elimination
peripheral
b
cells
date
november
time
est
location
virtual
poster
hall
abstract
number
additional
meeting
information
found
sitc
website
poster
presentation
available
events
presentations
section
company
website
shattuck
labs
shattuck
biotechnology
company
pioneering
development
fusion
proteins
new
class
biologic
medicine
treatment
patients
cancer
autoimmune
disease
compounds
derived
shattuck
proprietary
agonist
redirected
checkpoint
platform
simultaneously
inhibit
checkpoint
molecules
activate
costimulatory
molecules
within
single
therapeutic
company
lead
wholly
owned
program
designed
block
immune
checkpoint
simultaneously
agonize
pathway
evaluated
phase
trial
second
compound
evaluated
phase
trial
collaboration
takeda
pharmaceuticals
additionally
company
advancing
proprietary
gamma
delta
cell
engager
platform
designed
bridge
gamma
delta
cells
tumor
antigens
treatment
patients
cancer
shattuck
offices
austin
texas
durham
north
carolina
information
please
visit
investor
contact
conor
richardson
director
finance
shattuck
labs
investorrelations
media
contact
stephanie
ascher
managing
director
stern
investor
relations
